Compare WOLF & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | IMCR |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2025 | 2016 |
| Metric | WOLF | IMCR |
|---|---|---|
| Price | $24.87 | $29.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $24.00 | ★ $59.40 |
| AVG Volume (30 Days) | ★ 2.9M | 524.6K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | $249,428,000.00 |
| Revenue This Year | $14.87 | $9.30 |
| Revenue Next Year | $4.07 | $10.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.00 | ★ 43.05 |
| 52 Week Low | $13.49 | $27.50 |
| 52 Week High | $80.82 | $40.71 |
| Indicator | WOLF | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 45.65 |
| Support Level | $23.31 | $27.91 |
| Resistance Level | $26.70 | $31.11 |
| Average True Range (ATR) | 2.31 | 1.50 |
| MACD | 0.49 | 0.04 |
| Stochastic Oscillator | 61.73 | 39.13 |
Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.